The Zacks Analyst Blog Eli Lilly, Exxon Mobil, Costco and Flanigan's

In This Article:

For Immediate Releases

Chicago, IL – January 23, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include, Eli Lilly and Co. LLY, Exxon Mobil Corp. XOM, Costco Wholesale Corp. COST and Flanigan's Enterprises, Inc. BDL.

Here are highlights from Thursday’s Analyst Blog:

Top Analyst Reports for Eli Lilly, Exxon Mobil and Costco

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., Exxon Mobil Corp. and Costco Wholesale Corp., as well a micro-cap stock Flanigan's Enterprises, Inc.The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+18.2% vs. -1.7%). Demand for the company’s popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company’s key top-line drivers. Its new drugs contributed significantly to top-line growth in 2024. Lilly is also making rapid pipeline progress in areas like obesity, diabetes and Alzheimer’s.

However, sales of Mounjaro/Zepbound were disappointing in the second half of 2024 due to slower-than-expected growth, which has raised concerns about moderating demand for the drugs.

Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds. Estimates have declined ahead of fourth-quarter results. Lilly has a mixed record of earnings surprises in recent quarters.

(You can read the full research report on Eli Lilly here >>>)

Shares of Exxon Mobil have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+19.6% vs. +14.5%). The company’s high-value assets in the Permian Basin and Guyana drive robust production growth, doubling upstream earnings since 2019. The Pioneer acquisition and Guyana ramp-up have enhanced profitability, while a robust structural savings strengthen resilience.

With a lower exposure to debt capital, XOM supports steady cash flows, dividends, buybacks and investments in high-return projects. Expansion in low-carbon tech, including Baytown's hydrogen facility, positions it for future growth.

Yet, refining margins are pressured due to global capacity increases, with refining profits softening. The refining margin pressure intensifies the reliance on upstream operations which is vulnerable to fluctuating oil and gas prices. Commodity price volatility challenges profitability, especially as crude prices dipped in the third quarter.